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Abstract
Background—Prostate-specific antigen (PSA) measurements are increasingly used to monitor
men with localised prostate cancer (PCa), but there is little consensus about the method to use.
Objective—To apply age-specific predictions of PSA level (developed in men without cancer) to
one cohort of men with clinically identified PCa and one cohort of men with PSA-detected PCa.
We hypothesise that among men with clinically identified cancer, the annual increase in PSA level
would be steeper than in men with PSA-detected cancer.
Design, setting, and participants—The Scandinavian Prostatic Cancer Group 4 (SPCG-4)
cohort consisted of 321 men assigned to the watchful waiting arm of the SPCG-4 trial. The UK
cohort consisted of 320 men with PSA-detected PCa in the Prostate Testing for Cancer and
Treatment (ProtecT) study in nine UK centres between 1999 and 2007 who opted for monitoring
rather than treatment. Multilevel models describing changes in PSA level were fitted to the two
cohorts, and average PSA level at age 50, change in PSA level with age, and predicted PSA values
were derived.
Measurements—PSA level.
Results and limitations—In the SPCG-4 cohort, mean PSA at age 50 was similar to the
cancer-free cohort but with a steeper yearly increase in PSA level (16.4% vs 4.0%). In the UK
cohort, mean PSA level was higher than that in the cancer-free cohort (due to a PSA biopsy
threshold of 3.0 ng/ml) but with a similar yearly increase in PSA level (4.1%). Predictions were
less accurate for the SPCG-4 cohort (median observed minus predicted PSA level: 3?2.0 ng/ml;
interquartile range [IQR]: 3?7.6–0.7 ng/ml) than for the UK cohort (median observed minus
predicted PSA level: 3?0.8 ng/ml; IQR: 3?2.1–0.1 ng/ml).
Conclusions—In PSA-detected men, yearly change in PSA was similar to that in cancer-free
men, whereas in men with symptomatic PCa, the yearly change in PSA level was considerably
higher. Our method needs further evaluation but has promise for refining active monitoring
protocols.
Keywords
active surveillance; localised prostate cancer; PSA doubling time; PSA velocity; reference ranges
1. Introduction
Prostate cancer (PCa) is one of the most common newly detected cancers in men worldwide,
primarily because of the widespread use of prostate-specific antigen (PSA) testing. The
suitability of PSA for PCa population screening remains debatable [1,2], and there is
controversy over the most appropriate treatment for early PCa. While the Scandinavian
Prostatic Cancer Group 4 (SPCG-4) trial showed a survival benefit for radical surgery over
watchful waiting in men with clinically detected, localised disease [3,4], it is uncertain
whether such benefits would extend to men with earlier, PSA-detected PCa [5].
Most men diagnosed with localised PCa have high survival rates, particularly those with the
most common low-risk tumours [6,7]. Hence, there is increasing interest in monitoring men
with low-risk tumours to permit delay or avoidance of radical treatments [8–10], but there is
no consensus about the best methods for monitoring and/or surveillance or for detecting
progression [11]. Serial measures of PSA level are used consistently, but various aspects of
PSA kinetics are used to trigger intervention. Little information is available on longitudinal
changes in PSA levels in men that could establish ranges for benign PSA change against
which PSA measurements for an individual could be compared. A study combining
longitudinal studies of PSA levels in controls with men before diagnosis of cancer identified
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a linear change in log(PSA) for controls, with a change point for men with cancer followed
by a rapid rise in PSA level [12]. Cases that metastasised had more rapid increases in PSA
levels after this change point [12]. Data from SPCG-4 showed that higher PSA level at
baseline and faster yearly increase in PSA level were associated with, although not strongly
predictive of, adverse outcome [13].
In this paper, we examine whether age-specific predictions of PSA level (developed from a
population of cancer-free men) [14] can be applied to two very different cohorts: (1) men
who underwent watchful waiting as part of the SPCG-4 study [3] and (2) men who opted for
monitoring following population-based PSA testing in the Prostate Testing for Cancer and
Treatment (ProtecT) study in the United Kingdom. We hypothesised that in men with
clinically detected localised cancer (from the SPCG-4 cohort), the yearly change in PSA
level would be increased.
2. Methods
Age-specific reference ranges for PSA levels in cancer-free men were developed using serial
measurements of PSA level from 1462 men aged 50–78 yr (Krimpen cohort) [15]. Men with
a raised PSA level (>4 ng/ml) were investigated, and if PCa was found, they were excluded
[15]. A multilevel growth curve model was used to relate log(PSA) to age. The model
allowed for correlation between the yearly change in PSA level and baseline level of
log(PSA) and estimated the influence of individual characteristics on PSA level. Each man
has his own pattern of changing PSA level with age, and these patterns are assumed to be
normally distributed across a population average. This model allows PSA patterns to differ,
even among men with the same baseline characteristics [14]. In this way, each man can be
provided with his own reference ranges, accommodating his current PSA level and other
baseline characteristics and predicting his future PSA levels. Thus, future PSA pattern for a
man can be predicted, conditional on one observed PSA measurement, using the coefficients
and random effects from the multilevel model [14]. Such models have been used to predict
outcome following stroke [16], with technical aspects described in detail elsewhere [17].
Development of these models requires that men should have at least two PSA
measurements, but the model can include men with differing numbers of PSA measurements
taken at different ages.
2.1. Scandinavian Prostatic Cancer Group 4 cohort
From 1989 to 1999 the SPCG-4 trial enrolled 695 men from 14 centres in Sweden, Finland,
and Iceland [3]. Eligibility criteria included age <75 yr; newly diagnosed, untreated,
localised PCa verified by histologic examination, well differentiated or moderately well
differentiated, with a tumour stage of T0d (later changed to T1b), T1, or T2 (T1c was
included in 1994); health status permitting radical prostatectomy; life expectancy >10 yr; a
normal bone scan; and PSA level <50 ng/ml. Most had clinically identified T2 stage cancer,
with 12% having T1c tumours, and only 5% had case records showing that the cancer was
detected by PSA screening. Some 348 men were randomly assigned to watchful waiting,
receiving no initial treatment. This analysis used the 321 men who had at least two PSA
measurements, at least 4 mo between first and second PSA measurements, and a first PSA
measurement <8 mo after randomisation. The mean length of follow-up was 6.6 yr (standard
deviation [SD]: 3.5 yr).
2.2. United Kingdom cohort
Men aged 50–69 yr at randomly selected general practices underwent a PSA test as part of
the ProtecT study in nine UK centres between 1999 and 2007 [8]. Men with a PSA level
3?3.0 ng/ml had further diagnostic tests, including a 10-core prostate biopsy. Men with
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histologically proven PCa and clinical evidence that it was localised were invited to take
part in the randomised treatment trial comparing radical surgery, radical conformal
radiotherapy, and active monitoring (involving regular PSA tests). Men who refused to
participate in the ProtecT treatment trial and opted for monitoring formed the UK cohort for
this analysis. There were 320 men with at least two PSA tests, including the baseline test.
The study was approved by the Trent multicentre research ethics committee, and all
participants gave informed consent. The mean length of follow-up was 2.6 yr (SD: 1.6 yr).
2.3. Monitoring protocols
Participants in the SPGC-4 cohort were seen every 6 mo during the first 2 yr and then
annually for clinical examination and blood tests, including a PSA test. A bone scan and
chest radiograph were obtained annually until 1997; thereafter, chest radiographs were
obtained annually for the first 2 yr. Men in the UK cohort received PSA tests every 3 mo in
year 1 and every 6 mo thereafter. Rebiopsy was not routinely undertaken in either cohort.
Test results were reviewed annually, and patient and clinician decided whether to continue
with monitoring.
2.4. Statistical methods
Due to the skewed distribution of PSA levels, the outcome in all models was log(PSA).
Separate multilevel growth-curve models were fitted to log(PSA) for each cohort of men
with PCa, and the coefficients (describing the PSA level at age 50 and yearly change in PSA
level) were compared with those from cancer-free men (Krimpen model) [18]. These models
fit a separate regression line for each man by estimating PSA level at age 50 and yearly
change in PSA level as two correlated normal distributions (see section 3.2). A further
multilevel model was fitted to each cohort, including baseline Gleason score as an
explanatory variable; it treated both distributions as a linear variable and categorised them
(2–6, 7, and 8–10). Gleason score was allowed to affect both the intercept (PSA level at age
50) and the yearly change in PSA level. No other variables were considered for inclusion in
these models.
The individual pattern of change in PSA level with age for each man in both cohorts was
predicted using the coefficients from the respective multilevel models including age only.
These predictions were compared with those from the Krimpen model. Predictions were
made using a man’s first observed PSA measurement (using the model coefficients and
random effects [14]), and then repeated using his first two PSA measures. All statistical
analyses were performed using Stata v.9 (StataCorp, College Station, TX, USA) [19].
3. Results
3.1. Baseline data
Table 1 shows baseline PSA values by age group for each cohort. In these cross-sectional
data, PSA levels increase with age in the Krimpen and UK cohorts, with no age-related
increase in the SPCG-4 cohort. PSA values in the SPCG-4 cohort were highly variable, with
a few men having very high values. The Krimpen cohort was larger than either of the PCa
cohorts and had a greater proportion of men aged >70 yr. The SPCG-4 study cohort had a
wider spread of Gleason scores than the UK cohort and had more evidence of higher PSA
levels in men with higher Gleason scores (Table 2).
3.2. Model development
There were between 2 and 22 PSA measurements per participant in the SPCG-4 study
(mean: 10.5; SD: 4.5) and between 2 and 25 PSA measurements per participant in the UK
cohort (mean: 9.5; SD: 4.7). The coefficients from the cohort-specific multilevel models are
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shown in Table 3 compared with those from the Krimpen model. For the SPCG-4 cohort, the
mean PSA level at age 50 was similar to that from the Krimpen study but with a steeper age-
related increase in PSA level. Conversely, for the UK cohort the average PSA level (at age
50) was higher than that from the Krimpen study (because PSA level >3.0 ng/ml was one
inclusion criterion for the study) but with a similar age-related change in PSA level. The
average predicted patterns of change in PSA level with age (from the coefficients in Table 3)
for each of these three models are shown in Figure 1. The following equations were used for
the average patterns of PSA level:
For each of the cohorts of men with PCa, Gleason score at diagnosis was added to the model
(Table 4). Using the SPCG-4 cohort, there was no evidence for an association between
Gleason score and average PSA level (Table 4, p for trend = 0.24), but there was strong
evidence of a greater yearly increase in PSA level with higher Gleason scores (Table 4; p =
0.001 for trend). Similar results were obtained from the UK cohort, with less variation in
Gleason score; there was no evidence that a higher Gleason score was associated with
baseline PSA level (Table 4; p = 0.28) and with evidence of a greater yearly increase in PSA
level with higher Gleason scores (Table 4; p = 0.06). Thus, men with a higher Gleason score
have the same baseline PSA level as those with lower Gleason scores, but their PSA level
increases faster with age. The following equations were used for the average patterns of PSA
level with Gleason score:
A similar pattern was observed in both cohorts when Gleason score was used as a
categorical variable with three categories (2–6, 7, and 8–10); we found a lower yearly
increase in PSA level for Gleason scores 2–6 than for Gleason score 7, and we found little
evidence of a higher yearly increase in PSA for Gleason scores 8–10. There was no strong
evidence of a difference in baseline PSA between Gleason categories (2–6, 7, and 8–10) for
either cohort.
3.3. Model evaluation
Predictions of PSA level were calculated conditionally on the first and the first two observed
PSA measurements for the SPCG-4 cohort and the UK cohort, respectively, using the
respective model parameters and those derived from the Krimpen model (Table 5). For the
SPCG-4 cohort, both models were unable to predict PSA levels accurately (median
difference for Krimpen model conditional on first observation: 3?2.0; IQR: 3?7.6–0.7),
largely because of a small number of men with very high PSA levels. For the UK cohort, the
Krimpen model and the UK model (using the first observation and then using the first two
observations) performed well, with small differences between observed PSA level and the
predicted PSA level (median difference for Krimpen model using first observation: 3?0.8;
IQR: 3?2.1–0.1).
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4. Discussion
This is the first time that these longitudinal reference ranges allowing individually calibrated
predictions have been applied to PSA measures of men with PCa [14]. We modelled the
pattern of change of PSA level in two different large cancer populations and compared the
results to those obtained from a model derived from a reference, noncancer population
(Krimpen). The model derived from the UK cohort was very similar to the Krimpen model
calibrated to that population. The model derived from the SPCG-4 cohort had a greater
yearly increase in PSA than the calibrated Krimpen model. Hence, in men with PSA-
detected PCa, the yearly PSA change is similar to that in cancer-free men, whereas in men
diagnosed with PCa following clinical presentation, the yearly change in PSA level was
considerably higher. There is an urgent need to develop protocols that allow safe monitoring
and/or surveillance of men with low-risk and localised (T1c, Gleason <7) PCa, the majority
of whom will not develop clinically important, let alone advanced, disease in their lifetimes
[6,20]. Many monitoring protocols have been developed, but there is little consensus about
what should be measured or what constitutes evidence of risk of progression [11]. The
validation of such protocols is difficult, primarily because of the time required for clinically
relevant outcomes (ie, death or the development of metastases) to occur, and there are few
data sets with such outcomes from men with PSA-detected PCa. The method described in
this paper attempts to take into account the benign growth of the prostate and consequent
changes in PSA level over time. Further research, however, is required to investigate
whether patients at the highest risk of progression can be identified when their disease is still
curable by local treatment.
The differences found in the PSA patterns between the UK cohort and the SPCG-4 cohort
may be due to their different participant characteristics. The UK study population consists of
men diagnosed with PCa following communitywide PSA testing based at general practices,
whereas SPCG-4 men presented clinically to urologic centres. The UK men were younger
than those in the SPCG-4 study and had lower average PSA levels and Gleason scores.
Calculations of lead times for PCa suggest that UK men will have been diagnosed some 8–
12 yr before SPCG-4 men [21]. It is also important to note that the SPCG-4 cohort had a
much longer follow-up than the UK cohort (6.6 yr vs 2.6 yr) and, thus, contained many men
who had progressed to locally advanced and metastatic disease. These factors are likely to
account for the difference in age-related increase in PSA levels between the studies. Our
model suggests a yearly change in PSA level of 15% in the SPCG-4 study versus 4% in the
UK study. A study combining results from three longitudinal studies of PSA (up to time of
diagnosis with cancer) suggested similar rates of change of 2% per year in men without
cancer and 15% per year in men with localised disease [12]. These studies were undertaken
before the PSA screening era, so there may be many more men among the controls who had
undiagnosed PCa, which could account in part for the similarity between the estimated age-
related increases in the PSA-detected men in the UK study and those in cancer-free men
from the earlier studies.
It is encouraging that the Krimpen model and the UK model show similar increases in PSA
level with increasing age; a higher increase in the SPCG-4 cohort implies an increase in rate
of change in PSA level with increased disease severity or time since diagnosis. Thus, as we
hypothesised, age-related increase in PSA level seems to be higher for clinically detected
symptomatic cancer than for PSA-detected cancers. A potential advantage of the reference-
range method for monitoring men with PSA-detected PCa is its ease of use: serial PSA
measures can be plotted against the pattern predicted using the first PSA measurement.
Additionally, the method avoids concerns raised by day-to-day fluctuations in PSA level and
takes into account age and PSA level at the beginning of monitoring rather than just
observed PSA level, velocity, or relative increase, as in current protocols. It is unknown
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whether changes in PSA occur in advance of progression (indicating a role for PSA
monitoring) or are an expression of it (so that rapidly increasing PSA could identify those
who would benefit from early hormone therapy).
This study has some weaknesses. The original model is based on data from one community-
based study in the Krimpen area of the Netherlands. While we anticipate that these findings
should be generalisable, they may not be representative beyond Northern Europe. We have
no PSA measurements of men both before and after they developed cancer, so we cannot
examine a change-point model. Men in the Krimpen study were investigated for PCa if they
had PSA >4 ng/ml [15], so some men in the cancer-free Krimpen model may have had
undetected disease. This is, however, likely to be the case in any data set of men of this age
[22], and when later-detected cases of PCa were removed from the Krimpen data set, it
made little difference to the fitted model [14].
Considerable further research needs to be undertaken. These methods (and alternative
formulations) must be assessed for their ability to predict progressive disease. This requires
data on a large number of men undergoing active monitoring for many years, with
information on progression of disease (presence of metastases, death) obtained
independently of their PSA status (eg, all men restaged at the end of follow-up, regardless of
PSA level).
5. Conclusions
Yearly change in PSA level appears to be steeper in those with longer follow-up and with
more severe cancer (symptomatic as opposed to PSA detected). This factor may distinguish
men with cancer who are at low risk of progression from those who are at high risk. Our
method has promise for use in men undergoing active monitoring and/or surveillance but
requires further validation.
Take-home message
In men with localised prostate cancer, yearly change in prostate-specific antigen (PSA)
level was considerably higher in those whose cancer was detected through presentation of
symptoms than in those whose cancer was detected through PSA screening. Our
reference range method needs further evaluation but has promise for refining active
monitoring protocols.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Average patterns of change of prostate-specific antigen (PSA) level (ng/ml) with age (in
years) in men without cancer (Krimpen model) and in men with localised prostate cancer
(SPCG-4 cohort and UK cohort).
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Table 1
Distribution of baseline prostate-specific antigen (PSA) level by age at baseline for the Krimpen study, the Scandinavian Prostatic Cancer Group 4
(SPCG-4) cohort, and the UK cohort, showing median and interquartile range (IQR)
Krimpen study SPCG-4 cohort UK cohort
Age
group, yr
PSA median,
ng/ml (IQR)
n (%) PSA median,
ng/ml (IQR)
n (%) PSA median,
ng/ml (IQR)
n (%)
<50 1.1
(0.6–1.6)
8 (
0.2)
– 0 3.8
(1.7–4.1)
3 (
0.9)
51–55 0.9
(0.6–1.3)
309 (
9.5)
9.7
(4.2–20.6)
8 (
2.5)
4.2
(3.4–6.2)
39
(12.2)
56–60 1.0
(0.6–1.7)
377
(19.6)
12.0
(5.8–18.3)
44
(13.7)
4.9
(3.5–7.0)
68
(21.3)
61–65 1.1
(0.7–2.1)
351
(20.0)
8.9
(5.2–15.5)
95
(29.6)
4.9
(3.5–7.0)
116
(36.3)
66–70 1.4
(0.8–2.5)
266
(15.5)
8.8
(5.7–16.0)
117
(36.4)
5.1
(3.7–6.9)
93
(29.1)
>70 1.8
(1.0–3.4)
151
(35.1)
9.2
(5.8–16.3)
57
(17.8)
4.4 1 (
0.3)
Total 1.1
(0.7–2.0)
1462 9.2
(5.4–16.0)
321 4.8
(3.6–6.9)
320
Eur U
rol
.
 A
uthor m
anuscript; available in PM
C 2011 M
arch 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Tilling et al. Page 11
Table 2
Distribution of baseline prostate-specific antigen (PSA) level by Gleason score at baseline for the
Scandinavian Prostatic Cancer Group 4 (SPCG-4) cohort and the UK cohort, showing median and
interquartile range (IQR)
SPCG-4 cohort* UK cohort†
Gleason score PSA median,
ng/ml(IQR)
n (%) PSA median,
ng/ml (IQR)
n (%)
3 3.4 1 (0.3) – 0
4 6.7 (3.2–11.0) 41 (14.0) 6.1 (4.7–7.5) 2 (0.6)
5 10.0 (5.3–15.0) 75 (25.6) 4.4 (3.7–8.7) 7 (2.2)
6 9.2 (6.7–16.0) 80 (27.3) 4.7 (3.5–6.5) 256 (80.3)
7 11.0 (7.2–23.0) 75 (25.6) 5.4 (3.9–8.1) 52 (16.3)
8 10.5 (4.1–14.1) 18 (6.1) 6.4 (3.2–9.6) 2 (0.6)
9 17.8 (1.5–18.0) 3 (1.0) – 0
Total 9.6 (5.6–16.3) 293 4.8 (3.5–6.9) 319
*
Twenty-eight men missing Gleason data.
†
Two men missing Gleason data.
Eur Urol. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Tilling et al. Page 12
Table 3
Coefficients for the relationship between prostate-specific antigen (PSA) and age for the Krimpen study, the
Scandinavian Prostatic Cancer Group 4 (SPCG-4) cohort, and the UK cohort
Krimpen study SPCG-4 cohort UK cohort
PSA level at age 50, ng/ml (95% CI) 0.8
(0.7–0.8)
0.8 (0.6–1.2)   3.1
(2.7–3.6)
Relative increase in PSA per year in
age, % (95% CI)
  4.0
(3.7–4.5)
  16.4
(14.0–18.8)
  4.1
(3.1–5.2)
CI = confidence interval.
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Table 4
Coefficients for the relationship between prostate-specific antigen (PSA) level and Gleason score for the
Scandinavian Prostatic Cancer Group 4 (SPCG-4) cohort and the UK Cohort
SPCG-4 cohort UK cohort
Increase in PSA per one grade increase in Gleason
score, % (95% CI)
3?
(3?37.0–12.1)
3?
(3?36.8–17.2)
Change in yearly increase in PSA per one grade
increase, % (95% CI)
2.8 (1.1–4.6) 2.1 (3?0.1–4.3)
CI = confidence interval.
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Table 5
Predicted prostate-specific antigen (PSA) level using the first and first two observed PSA measurements from
the Krimpen study model parameters and from the parameters of the models developed on each data set
SPCG-4 cohort UK cohort
PSA median
level, ng/ml(
IQR)
Predicted-
observed median
level, ng/ml
(IQR)
PSA median
level, ng/ml
(IQR)
Predicted-
observed median
level, ng/ml
(IQR)
Using first
observation
N (observations) = 3042, n (men) =
321
N (observations) = 2726, n (men) =
320
Observed PSA
level, ng/ml
11.3
(5.5–23.0)
– 5.2 (3.8–7.9) –
Krimpen model 9.1 (5.3–15.3) 3?
(3?7.6–0.7)
4.5 (3.5–6.3) 3?
(3?2.1–0.1)
Study model 13.2
(7.6–23.1)
0.9 (3?2.8–5.5) 5.1 (4.0–7.1) 3?
(3?1.4–0.7)
Using first two
observations
N (observations) = 2721, n (men) =
313
N (observations) = 2407, n (men) =
320
Observed PSA
level, ng/ml
12 (5.7–24) – 5.3 (3.8–8.1) –
Krimpen model 9.9 (5.3–17.4) 3?
(3?6.4–0.9)
4.9 (3.8–6.9) 3?
(3?1.6–0.5)
Study model 12.4
(6.8–22.4)
0.6 (3?2.8–3.8) 5.1 (4.0–7.2) 3?
(3?1.4–0.7)
IQR = interquartile range; SPCG-4 = Scandinavian Prostatic Cancer Group study.
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